Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDFATHER-NSCLC-01: Visugromab plus pembrolizumab + pemetrexed + carboplatin versus placebo in first-line metastatic non-squamous NSCLC
2024-516792-32-01Phase 2Authorised
- Sponsor
- CatalYm
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in non-squamous non-small cell lung cancer comparing Visugromab combination arm with Placebo combination arm (2 arms). Planned start Jun 2025; status: authorised.
02
Drugs
visugromab
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on 2024-516792-32-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516792-32-01.